Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Completed · Phase 4 · Has a placebo group

Conditions studied: Psoriasis

In brief

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

Key facts

Study ID

NCT05478499

Run by

Bristol-Myers Squibb

People needed

154

Starts

2022-10-06

Expected to finish

2024-10-17

Last updated by the study team

2025-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
• Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
• Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
• ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
• Evidence of plaque psoriasis in a non-scalp area
• Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis

You may not qualify if…

• Target Disease Exceptions:
• Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0001 — Hot Springs, Arkansas, United States
• Local Institution - 0007 — Indianapolis, Indiana, United States
• Local Institution - 0041 — Louisville, Kentucky, United States
• Local Institution - 0022 — Rockville, Maryland, United States
• Local Institution - 0008 — Beverly, Massachusetts, United States
• Local Institution - 0047 — Bloomfield Hills, Michigan, United States
• Local Institution - 0002 — New Brighton, Minnesota, United States
• Local Institution - 0049 — East Windsor, New Jersey, United States
• Local Institution - 0051 — Kew Gardens, New York, United States
• Local Institution - 0003 — Portland, Oregon, United States
• Local Institution - 0005 — Pittsburgh, Pennsylvania, United States
• Local Institution - 0033 — Houston, Texas, United States
• Local Institution - 0004 — San Antonio, Texas, United States
• Local Institution - 0006 — Norfolk, Virginia, United States
• Local Institution - 0019 — Paris, France
• Local Institution - 0040 — Romans-sur-Isère, France
• Local Institution - 0044 — Rouen, France
• Local Institution - 0038 — Witten, Deutschland, Germany
• Local Institution - 0013 — Frankfurt am Main, Hesse, Germany
• Local Institution - 0048 — Hamburg, Germany
• Local Institution - 0012 — Lübeck, Germany
• Local Institution - 0011 — Mahlow, Germany
• Local Institution - 0026 — Krakow, Poland
• Local Institution - 0017 — Lodz, Poland
• Local Institution - 0014 — Rzeszów, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.